Download Advanced Endoscopic Therapy for Pancreatic Cancer

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
Advanced Endoscopic Therapy
for Pancreatic Cancer
Nathan Landesman, D.O.
Flint Gastroenterology Associates
February 28, 2015
Disclosures
• None
Emerging Role of Endoscopy
in Pancreatic Cancer
• Therapeutic
– Fiducial Placement
– Fine Needle Injection (FNI)
• Palliative
– Celiac Plexus Neurolysis (CPN)
– Relief of Obstruction
• Gastroduodenal
• Biliary
• Shifting emphasis from ERCP-based
approach to EUS-guided modalities
Therapeutic Endoscopic
Interventions
• Fiducial Placement
– Delineates extent of malignancy
– Quantifies respiratory-associated tumor motion
Therapeutic Endoscopic
Interventions
• Fiducial Placement Technique
– 19 or 22 gauge delivery system
– Loaded retrograde after stylet withdrawal
– Needle tip sealed with sterile bone wax
– Lesion accessed and fiducial deployed by stylet
or sterile water injection
Therapeutic Endoscopic
Interventions
• Fiducial Placement Technique
– Placement of at least 3 markers is preferred to
“triangulate” the malignancy
– > 4 markers to “box-in” the lesion is ideal
Therapeutic Endoscopic
Interventions
• Fiducial Placement Safety/Efficacy
– Prior studies reported technical failure with 19
gauge delivery system in the pancreatic head
and/or altered anatomy
– Newer trials report 88-97% success with only
minor complications
•
•
•
•
Equipment malfunction
Pain (Pancreatitis)
Bleeding/Infection
Migration
Therapeutic Endoscopic
Interventions
• Fiducial Placement Safety/Efficacy
– < 7% migration rate is likely overstated
• Decompression of gastroduodenal obstruction
• Decompression of biliary obstruction
Therapeutic Endoscopic
Interventions
• Fine Needle Injection (FNI)
– Activated lymphocytes/Oncolytic viruses
– Viral vectors (“Gene Therapy”)
– Ink marking of small lesions
Gene Therapy
• Delivery Vector
– Viral vs Non-viral
• Delivery Route
– Intravascular vs Intratumoral
• Tumor Targeting
– Gene Mutation/Transcriptional/Transductional
• Therapeutic Systems
– Virotherapy/Suicide Genes/Correction
Celiac Plexus Neurolysis (CPN)
• Bupivacaine and absolute alcohol
• 74-88% effective
– Head lesions may respond more favorably
– Single/Multiple Sites +/- Fenestrated needles
• Side Effects:
–
–
–
–
–
Bleeding/Infection
Diarrhea
Pain
Hypotension
Paralysis
Gastroduodenal Obstruction
in Pancreatic Cancer
• Uncovered metal prosthesis
of varying lengths
• Avoid coverage of major papilla if possible
– APC laser-assisted fenestration
• Surgical bypass
Biliary Obstruction
in Pancreatic Cancer
• Role of pre-operative biliary decompression
in resectable pancreatic head tumors
– van der Gaag NEJM 1/14/10 reported “serious
complication” rate of 39% and 74% in 2 arms
from biliary intervention
•
•
•
•
Pancreatitis
Bleeding
Biliary contamination
Pancreatic fistula/leak
– Post-op complication rates did not differ
significantly.
Biliary Obstruction
in Pancreatic Cancer
• Is plastic stenting for pancreatic cancer still
relevant in 2015? GIE review (Wang)
– Plastic stents 15-40x cheaper than metal
– Historically there was believed to be a cost
advantage in using plastic stents if:
• Diagnosis of malignancy was not established
• Patients expected to live < 3-6 months
• Patients undergoing operative resection < 3 months
Biliary Obstruction
in Pancreatic Cancer
• Is plastic stenting for pancreatic cancer still
relevant in 2015?
– Patency of 10 French plastic biliary stents
becomes an issue after 8 weeks with larger
caliber stents failing to increase patency
duration
– Plastic stents > 7 cm length are associated with
higher occlusion (and migration) rates.
Biliary Obstruction
in Pancreatic Cancer
• Multiple studies have demonstrated superior
patency of metal stents, which overrides
cost savings of plastic stenting
– More frequent ERCPs
– More frequent hospitalizations for occluded stents
– Possible sequelae of migrated plastic stents
Biliary Obstruction
in Pancreatic Cancer
• 2014 NCCN Guidelines on Pancreatic
Adenocarcinoma
– Short metal stent should be considered effective
first-line therapy for palliation (uncovered) or
bridge to surgery (covered) in borderline
resectable, non-metastatic patients assigned to
neoadjuvant therapy.
Biliary Obstruction
in Pancreatic Cancer
• Covered vs Uncovered metal biliary stents
– Comparable patency
– Higher migration risk of covered stents
– Higher cholecystitis and sludge risks of covered stents
– Fragmentation risk with covered stent removal
Biliary Obstruction
in Pancreatic Cancer
• EUS-guided drainage for difficult cases
– Transgastric
– Transduodenal
– Rendezvous
• IR assistance